Evidence map›Paper›PMID 34870106›Full record

ArticleJournal of Alzheimer's disease reports2021

Altered Cerebrospinal Fluid Exosomal microRNA Levels in Young-Onset Alzheimer's Disease and Frontotemporal Dementia.

Yi Jayne Tan, Benjamin Y X Wong, Ramanathan Vaidyanathan, Sivaramapanicker Sreejith, Sook Yoong Chia, Nagaendran Kandiah, Adeline S L Ng, Li Zeng

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Alzheimer's disease reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. [Recent advances on the role of exosomes in neurodegenerative diseases].Se pu = Chinese journal of chromatography · 2025
    Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Yi Jayne TanDepartment of Neurology, National Neuroscience Institute, Tan Tock Seng Hospital, Singapore.
Benjamin Y X WongDepartment of Neurology, National Neuroscience Institute, Tan Tock Seng Hospital, Singapore.
Ramanathan VaidyanathanDepartment of Biomedical Engineering, National University of Singapore, Singapore.
Sivaramapanicker SreejithBiomedical Institute for Global Health Research & Technology (BIGHEART), National University of Singapore, Singapore.
Sook Yoong ChiaNeural Stem Cell Research Lab, Department of Research, National Neuroscience Institute, Singapore.
Nagaendran KandiahDepartment of Neurology, National Neuroscience Institute, Tan Tock Seng Hospital, Singapore.
Adeline S L NgDepartment of Neurology, National Neuroscience Institute, Tan Tock Seng Hospital, Singapore.
Li ZengNeural Stem Cell Research Lab, Department of Research, National Neuroscience Institute, Singapore.
Tan Tock Seng Hospital · SGNanyang Technological University · SGNational University of Singapore · SGNational Neuroscience Institute · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundmicro-RNAs (miRNAs) are stable, small, non-coding RNAs enriched in exosomes. Their variation in levels according to different disease etiologies have made them a promising diagnostic biomarker for neurodegenerative diseases such as Alzheimer's disease (AD). Altered expression of miR-320a, miR-328-3p, and miR-204-5p have been reported in AD and frontotemporal dementia (FTD).

objectiveTo determine their reliability, we aimed to examine the expression of three exosomal miRNAs isolated from cerebrospinal fluid (CSF) of patients with young-onset AD and FTD (< 65 years), correlating with core AD biomarkers and cognitive scores.

methodsExosomes were first isolated from CSF samples of 48 subjects (8 controls, 28 AD, and 12 FTD), followed by RNA extraction and quantitative PCR to measure the expression of miR-320a, miR-328-3p, and miR-204-5p.

resultsExpression of all three markers (miR-320a (

conclusionOverall, we demonstrated miR-320a and miR-204-5p as reliable biomarkers for AD and FTD and report miR-328-3p as a novel AD biomarker.

Indexed as

Alzheimer’s diseasebiomarkercerebrospinal fluidexosomefrontotemporal dementiamiRNAsyoung-onset Alzheimer’s disease

Identifiers

PMID34870106
PMCPMC8609483
OpenAlexW3206603618

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.